What's Happening?
Greenberg Traurig, LLP has announced the addition of Gail Javitt as a shareholder in its Washington, D.C., office, significantly strengthening the firm's Health Care & FDA Practice. Javitt brings over 30 years of experience in food and drug law, specializing
in advising clients on FDA regulatory, compliance, and transactional matters. Her expertise spans a wide range of products, including medical devices, diagnostics, pharmaceuticals, biological products, and human cellular and tissue-based products (HCT/P). She counsels companies on various regulatory issues, from product development and commercialization to clinical trials, product approvals, post-market compliance, inspections, enforcement actions, and regulatory designations. Additionally, Javitt advises clinical laboratories and genomic interpretation companies on the evolving legal and regulatory framework for laboratory-developed tests and conducts regulatory due diligence for corporate transactions. This strategic hire is part of Greenberg Traurig's ongoing commitment to expanding its nationally recognized Health Care & FDA Practice and deepening its capabilities in the nation's capital.
Why It's Important?
The addition of Gail Javitt is important for Greenberg Traurig's Health Care & FDA Practice, enhancing its capacity to navigate the complex and rapidly evolving regulatory landscape for FDA-regulated industries. Her extensive experience provides significant value to clients, ranging from emerging companies to established industry leaders, who face challenges in product development, commercialization, and compliance. This move allows the firm to offer more comprehensive counsel to clients evaluating risk, pursuing new opportunities, and responding to changing requirements in the health care, life sciences, private equity, and M&A sectors. For the broader U.S. health care and life sciences industries, the availability of specialized legal expertise like Javitt's is crucial for fostering innovation while ensuring regulatory adherence. Companies operating in these sectors often face stringent FDA oversight, and expert guidance can mitigate legal risks, streamline product approvals, and facilitate market entry, ultimately impacting patient access to new medical technologies and treatments.
What's Next?
With Gail Javitt's integration, Greenberg Traurig is poised to further solidify its position as a leading legal advisor in the health care and FDA regulatory space. The firm will likely leverage her expertise to expand its client base and handle more complex and high-stakes regulatory matters. Clients in the medical device, pharmaceutical, and biotechnology sectors can expect enhanced support in navigating FDA regulations, particularly as innovation continues to accelerate and the legal and policy environment shifts. This strategic growth in Washington, D.C., suggests a continued focus by Greenberg Traurig on areas with significant regulatory impact. The firm may also continue to attract other top legal talent in specialized areas, further strengthening its ability to provide comprehensive legal services across various industries affected by federal regulations. This move also signals the firm's commitment to staying ahead of emerging issues in health care and life sciences, which could influence future legal strategies and policy discussions.
Beyond the Headlines
Gail Javitt's move to Greenberg Traurig highlights a broader trend in the legal industry where specialized expertise in highly regulated sectors, such as health care and FDA, is increasingly critical. As scientific discovery and technological advancements converge with health care, companies face a dynamic legal and policy environment. The demand for legal professionals who can interpret and apply complex regulations to novel products and services is growing. This trend underscores the ethical and legal dimensions of innovation, where the rapid pace of development often outstrips existing regulatory frameworks. Javitt's background, including her academic appointments and work on policy options for genetic technologies, points to the long-term shifts in how legal counsel will need to address not only compliance but also the ethical implications of new technologies. Her addition reflects the evolving nature of legal practice, moving beyond traditional litigation to encompass proactive regulatory strategy and policy shaping, particularly in areas like precision medicine and genetic testing.
